Investor Vida Ventures, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Vida Ventures, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-11-13 13G/A KNTE / Kinnate Biopharma Inc. 2,207,772 0
2024-05-03 13D KYTX / Kyverna Therapeutics, Inc. 4,777,060
2023-02-13 13G/A KNTE / Kinnate Biopharma Inc. 2,747,433 2,207,772
2023-02-10 13G/A PRAX / Praxis Precision Medicines, Inc. 2,939,329 1,469,665
2022-02-10 13G/A KNTE / Kinnate Biopharma Inc. 2,747,074 2,747,433
2021-02-16 13G PRAX / Praxis Precision Medicines, Inc. 2,939,329 2,939,329
2021-02-16 13G KNTE / Kinnate Biopharma Inc. 2,747,074 2,747,074
2021-02-16 13G KNTE / Kinnate Biopharma Inc. 2,747,074 2,747,074
2021-02-16 13G PRAX / Praxis Precision Medicines, Inc. 2,939,329 2,939,329